SCHEMBL2825458

SCHEMBL2825458

C#Cc1cc(C#C)cc(COc2ccc(OCC(=O)O)c(C)c2)c1

nearest known ligand 0.65

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 19/20 0.65
PPARG P37231 3/20 0.65
PPARA Q07869 3/20 0.58
FFAR1 O14842 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2069296 0.83 PPARD (0.71) PPARDPPARGPPARAFFAR1
SCHEMBL2070040 0.82 TSHR (0.48) PPARDPPARGPPARAFFAR1
SCHEMBL2822164 0.81 PPARD (0.70) PPARDPPARGPPARAFFAR1
SCHEMBL2069836 0.80 PPARD (0.73) PPARDPPARGPPARA
SCHEMBL3385737 0.80 PPARD (0.69) PPARDPPARGPPARAFFAR1
SCHEMBL2068107 0.80 PPARD (0.58) PPARDPPARGPPARAFFAR1
SCHEMBL13292264 0.77 PPARD (1.00) PPARDPPARGPPARAFFAR1
SCHEMBL12646903 0.76 PPARD (1.00) PPARDPPARGPPARAFFAR1
SCHEMBL13292286 0.75 PPARD (0.84) PPARDPPARGPPARAFFAR1
SCHEMBL13292318 0.74 PPARD (0.73) PPARDPPARGPPARAFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1745003-B1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE HIGH POINT PHARMACEUTICALS LLC (US) 2010-10-27 EP disclosed
US-20090209588-A1 Novel compounds, their preparation and use NOVO NORDISK A/S (DK) 2009-08-20 US disclosed
EP-1745003-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2007-01-24 EP disclosed
WO-2005105726-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209588-A1 Novel compounds, their preparation and use PPARG, PPARD, GPR119 PPARD 2/4885PPARG 1/4885PPARA 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.